GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
A 35-year-old has seen no hair regrowth after 9 months using treatments including finasteride, pyrilutamide, microneedling, ketoconazole shampoo, and topical dutasteride, but experienced side effects with RU58841. Commenters suggest starting minoxidil for better results and question why it wasn't included from the beginning.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
A 24-year-old has been using finasteride, minoxidil, and ketoconazole shampoo for 9 months to address hair loss, reporting slow but noticeable progress with some regrowth. They also occasionally used a dermastamp and shared photos to show their progress.
People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
A user shared a 9-month update on using 0.25mg finasteride daily for hair maintenance, reporting no significant side effects and considering whether to add other treatments like a dermastamp or ketoconazole. The user has not used minoxidil, believes it's unnecessary unless hair loss is severe, and occasionally takes biotin supplements.
A user shared their experience on day 9 after a hair transplant, mentioning the use of vitamin E oil and conditioner to remove scabs. They received positive feedback on their progress and were advised to be patient for noticeable results in a few months.
A user shared their 9-month hair loss treatment progress using oral finasteride, oral minoxidil, a topical solution with minoxidil and finasteride, microneedling, and ketoconazole shampoo. They are happy with the results and considering whether a hair transplant will be necessary.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
A user shared their 9-month progress using 1mg daily finasteride, noting initial side effects like low libido and ED that resolved over time, and advised staying on the treatment for at least a year before considering a hair transplant. Other users suggested adding minoxidil for better results and recommended using ketoconazole shampoo for dandruff.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.
Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.